Park­er In­sti­tute backs an up­start biotech look­ing to de­vel­op a new, con­vert­ible CAR-T

The bil­lion­aire-backed Park­er In­sti­tute for Can­cer Im­munother­a­py is in­vest­ing and part­ner­ing with a biotech their re­searchers be­lieve has the po­ten­tial to de­vel­op a new-mod­el CAR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.